ASX Announcement

Imugene selected for Poster Presentation at Prestigious ASH Annual Meeting in Louisiana

Sydney, Australia, 5 November 2026: Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, is pleased to announce that an abstract regarding azer-cel has been selected for a poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from 12-15 December 2026 in New Orleans, Louisiana.

The ASH Annual Meeting is the world's premier event for advancing hematology research and science, attracting over 30,000 global clinicians, researchers, and industry leaders. Acceptance for poster presentation following ASH's rigorous peer-review process reflects the scientific merit and clinical interest in azer-cel's Phase 1b clinical trial data.

Imugene's abstract, titled "Safety and efficacy of azer-cel, an allogeneic CD19-directed CAR T-cell therapy, with concomitant Bruton tyrosine kinase inhibitor therapy in patients with relapsed/refractory B-cell malignancies", has been selected for poster presentation within the session "Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II."

The poster presentation will take place on 13 December 2026, from 6:00pm – 8:00pm US Central Standard Time at the New Orleans Ernest N. Morial Convention Center in Louisiana.

Following its release, the poster will be available on Imugene's website at https://imugene.com/investors/conference-presentations/

Imugene's Executive Chairman, Paul Hopper, said: "We are eager to share emerging data from our Phase 1b study in non-Hodgkin lymphomas and highlight the potential for azer-cel when combined with BTK inhibitors in patients who have previously progressed on prior BTKi therapy. Presenting data at the world's premier hematology congress allows us to engage directly with international experts and showcase the broad potential of our allogeneic CAR T platform, particularly in those with limited treatment options."

For more information please contact:

General Investor Enquiries
shareholderenquiries@imugene.com

Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Imugene is focused on developing azer-cel for patients with B-cell cancers whose disease has progressed on existing treatments, including CAR T and BTK inhibitors.

Release authorised by the Executive Chairman, Imugene Limited.